Species-Dependent Limitations of Murine Myocardium for Investigating the Combined Inotropic Effects of SERCA2a Stimulation and Myofilament Ca 2+ Sensitization
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Impaired sarcoplasmic reticulum Ca 2+ handling and myofilament function both contribute to contractile dysfunction in heart failure. A previous study in failing human myocardium showed that combining the SERCA2a activator istaroxime (ISTA) with the Ca 2+ sensitizer levosimendan (LEVO) produces greater positive inotropy than either drug alone. However, human multicellular preparations did not allow comprehensive investigation of the underlying cellular mechanisms. We therefore assessed contractile performance and Ca 2+ dynamics in murine multicellular myocardial preparations and ventricular cardiomyocytes treated with ISTA (20 µM), LEVO (0.5 µM), or their combination. ISTA improved developed force, contraction–relaxation kinetics, and mechanical restitution. These effects were associated with increased Ca 2+ transient amplitude, accelerated Ca 2+ rise and decay, and enhanced sarcoplasmic reticulum reloading. Adding LEVO produced no further mechanical benefit and only minor changes in Ca 2+ handling. LEVO alone elicited heterogeneous contractile responses and increased myofilament Ca 2+ sensitivity in only a minority of cardiomyocytes, while consistently accelerating Ca 2+ transient decay. This effect was reproduced by the phosphodiesterase-3 inhibitor cilostamide, after which LEVO caused no significant additional change, consistent with a contribution of downstream cAMP–PKA signaling to the acceleration of Ca 2+ removal. Thus, limited murine responsiveness to LEVO-mediated myofilament sensitization prevented mechanistic reconstruction of the additive inotropic effect observed in human myocardium, highlighting a species-dependent limitation of the mouse model for studying this combined therapy.